Therapy with intravenous immunoglobulins: complications and side-effects
- PMID: 14530624
- DOI: 10.1159/000073059
Therapy with intravenous immunoglobulins: complications and side-effects
Abstract
Therapy with intravenous immunoglobulins (IVIG) is thought to be a safe treatment for a number of immune-mediated neurological diseases. Published data about prevalence of adverse effects range from 11 to 81%. The purpose of our study was to present a representative view on adverse effects by analysis of a large cohort of patients treated by IVIG. In a prospective study, we analysed 117 patients (age 17-79 years) who were treated with IVIG for various neurological diseases including chronic inflammatory demyelinating polyneuropathy, diabetic amyotrophy, inclusion body myositis, multiple sclerosis, Guillain-Barré syndrome, Miller-Fisher syndrome, multifocal motor neuropathy, myasthenia gravis and polymyositis. IVIG therapy was applied at a dose of 0.4 g/kg body weight/day in a total of 408 therapy courses. 42.7% showed adverse events. The majority of patients presented with minor adverse effects, mostly asymptomatic laboratory changes. Rash or mild headache occurred in 8 patients, especially when IVIG was given with infusion flow higher than 10 g/h. Two patients showed a severe complication with deep vein thrombosis. In summary, beside its effectiveness in immune mediated neurological diseases, therapy with IVIG seems to be a safe therapy. Most patients show no or minor adverse effects. Patients with pre-existent disorders like heart or renal insufficiency or immobilised patients, however, may be at higher risk for complications.
Copyright 2003 S. Karger AG, Basel
Similar articles
-
Adverse effects of treatment with intravenous immunoglobulins for neurological diseases.J Neurol. 2006 Sep;253 Suppl 5:V75-9. doi: 10.1007/s00415-006-5013-z. J Neurol. 2006. PMID: 16998759 Review.
-
Intravenous immunoglobulin in autoimmune neuromuscular diseases.JAMA. 2004 May 19;291(19):2367-75. doi: 10.1001/jama.291.19.2367. JAMA. 2004. PMID: 15150209 Review.
-
Intravenous immune globulin therapy for neurologic diseases.Ann Intern Med. 1997 May 1;126(9):721-30. doi: 10.7326/0003-4819-126-9-199705010-00008. Ann Intern Med. 1997. PMID: 9139559 Review.
-
Side effects of intravenous immunoglobulins in neurological autoimmune disorders--a prospective study.J Neurol. 2003 Jul;250(7):818-21. doi: 10.1007/s00415-003-1085-1. J Neurol. 2003. PMID: 12883923
-
Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.Muscle Nerve. 2016 May;53(5):683-9. doi: 10.1002/mus.24942. Epub 2016 Jan 19. Muscle Nerve. 2016. PMID: 26467654
Cited by
-
Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review.Clin Rheumatol. 2012 May;31(5):801-6. doi: 10.1007/s10067-012-1940-5. Epub 2012 Jan 26. Clin Rheumatol. 2012. PMID: 22274797 Review.
-
Initial and long-term management of autoimmune neuropathies.CNS Drugs. 2005;19(12):1033-48. doi: 10.2165/00023210-200519120-00005. CNS Drugs. 2005. PMID: 16332144 Review.
-
Intravenous immunoglobulin: adverse effects and safe administration.Clin Rev Allergy Immunol. 2005 Dec;29(3):173-84. doi: 10.1385/CRIAI:29:3:173. Clin Rev Allergy Immunol. 2005. PMID: 16391392 Review.
-
Anti-GT1a and anti-GQ1b immunoglobulin G antibody positivity with overlapping Miller Fisher/Guillain-Barré syndromes and prominent headache: a case report.J Int Med Res. 2023 Jul;51(7):3000605231189114. doi: 10.1177/03000605231189114. J Int Med Res. 2023. PMID: 37523503 Free PMC article.
-
Immunoglobulin for multifocal motor neuropathy.Cochrane Database Syst Rev. 2022 Jan 11;1(1):CD004429. doi: 10.1002/14651858.CD004429.pub3. Cochrane Database Syst Rev. 2022. PMID: 35015296 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
